EGFR and non-small cell lung carcinoma: The concordance rate between BALF- and tissue-based EGFR genotyping was 98.5%, compared to 43.9% between plasma cfDNA- and tissue-based EGFR genotyping, highlighting the potential of BALF liquid EGFR testing as a replacement for conventional tissue-based genotyping, at least in patients with advanced non-squamous NSCLC.